513.20
+2.94%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About SMS Pharmaceuticals
Its shares trade on NSE under the ticker SMSPHARMA.NS. It has been listed since 25 February 2007. In the fiscal year to 31 March 2026, it reported revenue of ₹8.83bn and net income of ₹1.02bn. At that date it held total assets of ₹13.62bn and shareholders' equity of ₹7.86bn.
SMS Pharmaceuticals Ltd. is a holding company, which engages in the research, development and marketing of active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2007-02-25. The firm is engaged in the business of manufacturing of active pharma ingredients and their intermediates. Its product categories include anti-ulcer, anti-inflammatory, anti-migraine, ant-diabetic, anti-coagulant, anti-viral, anti-retroviral, anti-psychotic and others. The firm products include ranitidine, famotidine, pantoprazole sodium, itraconazole, lanoconazole, luliconazole, ibuprofen, Dex ibuprofen, fenoprofen calcium, sumatriptan, almotriptan, zolmitriptan, rizatriptan, Ele triptan, vildagliptin, sitagliptin, rosiglitazone, empagliflozin, dapagliflozin, tenofovir, dolutegravir, raltegravir, lamivudine, efavirenz, apixaban, rivaroxaban, levetiracetam, perampanel and lamotrigine. The firm has manufacturing facilities at Bachupally, Hyderabad, Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram District, Andhra Pradesh.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 25 Feb 2007
- Employees
- 1,095
- Website
- smspharma.com ↗
Leadership
Pay as last reported
- Shri. Ramesh PotluriExecutive Chairman of the Board, Managing Director, since 1990₹38.1m
- Sri. Lakshmi TammineediChief Financial Officer
- Mr. Thirumalesh TummaChief Compliance Officer, Company Secretary
- Mr. Vamsi PotluriAdditional Director, since 2020₹38.1m
- Mr. Trilok PotluriNon-Executive Non-Independent Director
- Dr. Sunkara PrasadNon-Executive Non Independent Director
- Mrs. Shanti BolleniNon-Executive Independent Director
- Dr. Suresh GangavarapuNon-Executive Independent Director
- Mr. Shravan KudaravalliNon-Executive Independent Director₹310,000
- Mr. Sarvepalli SrinivasAdditional Non-Executive Independent Director₹75,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Hyderabad, Telangana with manufacturing facilities in Bachupally and Kandivalasa.
- Employs 1,095 full-time employees as a holding company in the pharmaceutical sector.
- Offers a diverse range of products including anti-ulcer, anti-inflammatory, and anti-diabetic drugs.
Weaknesses
- Operates as a holding company without specified manufacturing details beyond facility locations.
- No mention of research and development investment or innovation capabilities.
- Limited information on market share or competitive positioning within the pharmaceutical industry.
Opportunities
- Expansion into emerging markets for active pharmaceutical ingredients and intermediates.
- Growing demand for specialized pharmaceutical products like anti-retroviral and anti-viral drugs.
- Potential for increased manufacturing capacity at existing facilities in Hyderabad and Andhra Pradesh.
Threats
- Dependence on a narrow product portfolio including specific drugs like ranitidine and famotidine.
- Regulatory challenges in the pharmaceutical sector affecting manufacturing and marketing.
- Competition from larger pharmaceutical companies with broader product lines.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.